XPERI INC (XPER)

US98423J1016 - Common Stock

9.04  +0.12 (+1.35%)

Fundamental Rating

2

Overall XPER gets a fundamental rating of 2 out of 10. We evaluated XPER against 284 industry peers in the Software industry. XPER may be in some trouble as it scores bad on both profitability and health. XPER has a valuation in line with the averages, but it does not seem to be growing.



1

1. Profitability

1.1 Basic Checks

XPER had positive earnings in the past year.
XPER had a negative operating cash flow in the past year.
In the past 5 years XPER always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: XPER reported negative operating cash flow in multiple years.

1.2 Ratios

XPER's Return On Assets of -13.80% is on the low side compared to the rest of the industry. XPER is outperformed by 67.03% of its industry peers.
XPER's Return On Equity of -22.53% is in line compared to the rest of the industry. XPER outperforms 41.94% of its industry peers.
Industry RankSector Rank
ROA -13.8%
ROE -22.53%
ROIC N/A
ROA(3y)-45.79%
ROA(5y)-31.11%
ROE(3y)-71.46%
ROE(5y)-48.38%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 76.45%, XPER is in the better half of the industry, outperforming 70.61% of the companies in the same industry.
XPER's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for XPER so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 76.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.88%
GM growth 5Y-4.4%

2

2. Health

2.1 Basic Checks

XPER does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XPER has been increased compared to 1 year ago.
The number of shares outstanding for XPER has been reduced compared to 5 years ago.
The debt/assets ratio for XPER is higher compared to a year ago.

2.2 Solvency

XPER has an Altman-Z score of -0.59. This is a bad value and indicates that XPER is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.59, XPER is not doing good in the industry: 75.63% of the companies in the same industry are doing better.
XPER has a Debt/Equity ratio of 0.13. This is a healthy value indicating a solid balance between debt and equity.
XPER's Debt to Equity ratio of 0.13 is in line compared to the rest of the industry. XPER outperforms 48.03% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Altman-Z -0.59
ROIC/WACCN/A
WACC11.27%

2.3 Liquidity

XPER has a Current Ratio of 1.29. This is a normal value and indicates that XPER is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.29, XPER is doing worse than 61.65% of the companies in the same industry.
XPER has a Quick Ratio of 1.27. This is a normal value and indicates that XPER is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of XPER (1.27) is worse than 62.72% of its industry peers.
Industry RankSector Rank
Current Ratio 1.29
Quick Ratio 1.27

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 1480.00% over the past year.
XPER shows a decrease in Revenue. In the last year, the revenue decreased by -2.12%.
Measured over the past years, XPER shows a small growth in Revenue. The Revenue has been growing by 5.12% on average per year.
EPS 1Y (TTM)1480%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%737.5%
Revenue 1Y (TTM)-2.12%
Revenue growth 3Y11.5%
Revenue growth 5Y5.12%
Sales Q2Q%1.92%

3.2 Future

The Earnings Per Share is expected to grow by 618.49% on average over the next years. This is a very strong growth
Based on estimates for the next years, XPER will show a decrease in Revenue. The Revenue will decrease by -1.68% on average per year.
EPS Next Y4256.5%
EPS Next 2Y618.49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-5.5%
Revenue Next 2Y-1.68%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

6

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 13.10, which indicates a correct valuation of XPER.
XPER's Price/Earnings ratio is rather cheap when compared to the industry. XPER is cheaper than 91.04% of the companies in the same industry.
XPER's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.28.
The Price/Forward Earnings ratio is 9.11, which indicates a very decent valuation of XPER.
Based on the Price/Forward Earnings ratio, XPER is valued cheaper than 94.62% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.53. XPER is valued rather cheaply when compared to this.
Industry RankSector Rank
PE 13.1
Fwd PE 9.11

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
XPER's earnings are expected to grow with 618.49% in the coming years. This may justify a more expensive valuation.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y618.49%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

XPER does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

XPERI INC

NYSE:XPER (1/15/2025, 12:30:36 PM)

9.04

+0.12 (+1.35%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)N/A N/A
Inst Owners89.54%
Inst Owner Change0.05%
Ins Owners2.1%
Ins Owner Change0.03%
Market Cap405.26M
Analysts84
Price Target19.13 (111.62%)
Short Float %3%
Short Ratio2.83
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)318.96%
Min EPS beat(2)181.42%
Max EPS beat(2)456.51%
EPS beat(4)4
Avg EPS beat(4)203.21%
Min EPS beat(4)66.19%
Max EPS beat(4)456.51%
EPS beat(8)8
Avg EPS beat(8)137.68%
EPS beat(12)11
Avg EPS beat(12)98.3%
EPS beat(16)15
Avg EPS beat(16)82.13%
Revenue beat(2)0
Avg Revenue beat(2)-1.98%
Min Revenue beat(2)-3.63%
Max Revenue beat(2)-0.34%
Revenue beat(4)0
Avg Revenue beat(4)-3.1%
Min Revenue beat(4)-4.58%
Max Revenue beat(4)-0.34%
Revenue beat(8)1
Avg Revenue beat(8)-2.1%
Revenue beat(12)1
Avg Revenue beat(12)-13.61%
Revenue beat(16)1
Avg Revenue beat(16)-18.79%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-35.62%
EPS NY rev (1m)0%
EPS NY rev (3m)43.66%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.52%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.23%
Valuation
Industry RankSector Rank
PE 13.1
Fwd PE 9.11
P/S 0.8
P/FCF N/A
P/OCF N/A
P/B 1.07
P/tB 1.99
EV/EBITDA N/A
EPS(TTM)0.69
EY7.63%
EPS(NY)0.99
Fwd EY10.98%
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-0.8
OCFYN/A
SpS11.34
BVpS8.42
TBVpS4.54
PEG (NY)0
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.8%
ROE -22.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 76.45%
FCFM N/A
ROA(3y)-45.79%
ROA(5y)-31.11%
ROE(3y)-71.46%
ROE(5y)-48.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.88%
GM growth 5Y-4.4%
F-Score4
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity 0.13
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.51%
Cap/Sales 3.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.29
Quick Ratio 1.27
Altman-Z -0.59
F-Score4
WACC11.27%
ROIC/WACCN/A
Cap/Depr(3y)13.95%
Cap/Depr(5y)11.08%
Cap/Sales(3y)2.4%
Cap/Sales(5y)2.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1480%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%737.5%
EPS Next Y4256.5%
EPS Next 2Y618.49%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-2.12%
Revenue growth 3Y11.5%
Revenue growth 5Y5.12%
Sales Q2Q%1.92%
Revenue Next Year-5.5%
Revenue Next 2Y-1.68%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y26.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year494.64%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-132.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-73.3%
OCF growth 3YN/A
OCF growth 5Y-78.5%